Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 57.0% in September

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 43,900 shares, a decline of 57.0% from the August 31st total of 102,200 shares. Approximately 1.5% of the shares of the company are sold short. Based on an average daily volume of 4,120,000 shares, the short-interest ratio is presently 0.0 days. Based on an average daily volume of 4,120,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.5% of the shares of the company are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on APVO shares. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Roth Capital upgraded Aptevo Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 16th. Finally, Zacks Research upgraded Aptevo Therapeutics to a “hold” rating in a research note on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy”.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Birchview Capital LP acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned 1.32% of Aptevo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Stock Performance

APVO stock opened at $1.45 on Friday. The company’s 50 day moving average is $1.91 and its 200 day moving average is $8.54. Aptevo Therapeutics has a 1-year low of $1.32 and a 1-year high of $381.10.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($8.40) earnings per share for the quarter, topping the consensus estimate of ($83.20) by $74.80. Research analysts forecast that Aptevo Therapeutics will post -15.84 earnings per share for the current fiscal year.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.